OPTICAL AND FUNCTIONAL PERFORMANCE OF PHAKIC ANGLE-SUPPORTED INTRAOCULAR LENS FOR THE CORRECTION OF HIGH MYOPIA IN 18-MONTHS FOLLOW-UP STUDY

To investigate the safety, the efficacy and stability of the AcrySof phakic angle-supported intraocular lens (IOL) (Alcon Laboratories, Inc., Fort Worth, TX) for correction of moderate-to-high myopia in adults. 12 patients (18 eyes) with moderate-to-high myopia underwent implantation of the AcrySof phakic angle-supported IOL. Best spectacle-corrected visual acuity (BSCVA), uncorrected distance visual acuity (UCVA), predictability and stability of mean manifest refraction spherical equivalent (MRSE), adverse events, endothelial cell density, corneal and total ocular aberrations and rotation of the IOL were measured. The mean follow-up was 18 months (± 4 months). At 18 months, the mean UDVA was 0.83 and the mean BSCVA was 0.97. The mean MRSE was -0.29 D. The mean percentage change in central endothelial cell density 18 months after surgery was -3.4%. No adverse events were observed. Wavefront measurements revealed a significant reduction in terms of high order aberrations between pre-operative and post-operative 18 months values. The analysis of the rotation showed a little variation (mean rotation of 5.4°) between postoperative 1 month and postoperative 18 months visits. The AcrySof phakic angle-supported IOL yielded excellent refractive correction and predictability with optimal safety. The study demonstrates preliminary support for an high stability of the IOL at 18 months follow-up.